BR112022023199A2 - Certas composições químicas e métodos de uso das mesmas - Google Patents

Certas composições químicas e métodos de uso das mesmas

Info

Publication number
BR112022023199A2
BR112022023199A2 BR112022023199A BR112022023199A BR112022023199A2 BR 112022023199 A2 BR112022023199 A2 BR 112022023199A2 BR 112022023199 A BR112022023199 A BR 112022023199A BR 112022023199 A BR112022023199 A BR 112022023199A BR 112022023199 A2 BR112022023199 A2 BR 112022023199A2
Authority
BR
Brazil
Prior art keywords
methods
chemical compositions
certain chemical
disorder
disease
Prior art date
Application number
BR112022023199A
Other languages
English (en)
Portuguese (pt)
Inventor
W Konradi Andrei
Huang Chun-Hao
Lee Ko-Chuan
Original Assignee
Algen Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algen Biotechnologies Inc filed Critical Algen Biotechnologies Inc
Publication of BR112022023199A2 publication Critical patent/BR112022023199A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112022023199A 2020-05-15 2021-05-14 Certas composições químicas e métodos de uso das mesmas BR112022023199A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063025474P 2020-05-15 2020-05-15
PCT/US2021/032495 WO2021231892A1 (en) 2020-05-15 2021-05-14 Certain chemical compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112022023199A2 true BR112022023199A2 (pt) 2023-04-04

Family

ID=76270111

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022023199A BR112022023199A2 (pt) 2020-05-15 2021-05-14 Certas composições químicas e métodos de uso das mesmas

Country Status (12)

Country Link
US (2) US11591322B2 (https=)
EP (1) EP4149941B1 (https=)
JP (1) JP2023526332A (https=)
KR (1) KR20230051127A (https=)
CN (1) CN116261561B (https=)
AU (1) AU2021273072A1 (https=)
BR (1) BR112022023199A2 (https=)
CA (1) CA3178813A1 (https=)
ES (1) ES3054109T3 (https=)
IL (1) IL298219A (https=)
MX (1) MX2022014356A (https=)
WO (1) WO2021231892A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3054109T3 (en) 2020-05-15 2026-01-29 Algen Biotechnologies Inc Certain chemical compositions and methods of use thereof
WO2023086417A1 (en) * 2021-11-11 2023-05-19 Algen Biotechnologies, Inc. Compounds and methods of use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4932412A (en) 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
EP1223952B1 (en) 1999-10-07 2008-04-16 Carlos Estuardo Aguilar-Cordova Methods for treatment of solid tumors and metastasis by gene therapy
WO2004110350A2 (en) 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
WO2006071958A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
WO2012101065A2 (en) * 2011-01-28 2012-08-02 Novartis Ag Pyrimidine biaryl amine compounds and their uses
WO2012101063A1 (en) * 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
CN103339110A (zh) * 2011-01-28 2013-10-02 诺瓦提斯公司 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途
WO2012101066A1 (en) 2011-01-28 2012-08-02 Novartis Ag Pyridine biaryl amine compounds and their uses
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
EP3126525B1 (en) 2014-04-04 2020-02-19 Memorial Sloan-Kettering Cancer Center Method and kits for identifying of cdk9 inhibitors for the treatment of cancer
NZ734082A (en) 2015-01-20 2019-01-25 Boehringer Ingelheim Animal Health Usa Inc Anthelmintic compounds, compositions and method of using thereof
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
EP3874045A4 (en) 2018-10-31 2022-09-07 The Regents of The University of California Methods and kits for identifying cancer treatment targets
CN114025772A (zh) 2019-04-24 2022-02-08 纪念斯隆凯特琳癌症中心 用于治疗ras突变体癌症的组合物和方法
JP7677914B2 (ja) 2019-06-21 2025-05-15 アルゲン バイオテクノロジーズ,インク. 標的遺伝子を特定するための方法およびシステム
EP4126918A4 (en) 2020-03-31 2024-05-29 The Regents of the University of California COMPOSITIONS AND METHODS FOR IDENTIFYING HOST CELL TARGET PROTEINS FOR THE TREATMENT OF RNA VIRUS INFECTIONS
ES3054109T3 (en) 2020-05-15 2026-01-29 Algen Biotechnologies Inc Certain chemical compositions and methods of use thereof
EP4185867A4 (en) 2020-07-22 2024-08-07 Algen Biotechnologies, Inc. Methods and systems for determining drug effectiveness
WO2023086417A1 (en) 2021-11-11 2023-05-19 Algen Biotechnologies, Inc. Compounds and methods of use thereof

Also Published As

Publication number Publication date
CN116261561A (zh) 2023-06-13
US20220289725A1 (en) 2022-09-15
US20230295135A1 (en) 2023-09-21
EP4149941A1 (en) 2023-03-22
CA3178813A1 (en) 2021-11-18
US12264152B2 (en) 2025-04-01
AU2021273072A1 (en) 2022-12-15
KR20230051127A (ko) 2023-04-17
ES3054109T3 (en) 2026-01-29
IL298219A (en) 2023-01-01
US11591322B2 (en) 2023-02-28
CN116261561B (zh) 2025-10-31
JP2023526332A (ja) 2023-06-21
MX2022014356A (es) 2023-03-09
WO2021231892A1 (en) 2021-11-18
EP4149941B1 (en) 2025-09-03

Similar Documents

Publication Publication Date Title
BR112022008858A2 (pt) Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
EA202190630A1 (ru) Способы комбинированной терапии
BR112022020769A2 (pt) Compostos de 2,4-dioxopirimidina de inibição de cd73
BR112023001956A2 (pt) Composto de fórmula (ia), (ib), (ic) ou (ii), composição farmacêutica, composto para uso ou composição farmacêutica para uso em um método de tratamento de câncer
MX391720B (es) Terapia combinada para tratar cáncer.
UA102669C2 (xx) Застосування інгібіторів dpp iv$применение ингибиторов dpp iv
MX387885B (es) Inhibidores de ezh2 para tratar linfomas.
CY1116344T1 (el) Κυτταρα προερχομενα απο ιστο ομφαλιου λωρου για την θεραπεια νευροπαθητικου πονου και σπαστικοτητας
EA202092154A1 (ru) Комбинированная терапия
BR112015008447A2 (pt) métodos para tratar câncer
CY1106601T1 (el) Χρηση του παραγωγου κουιναζολινης zd6474 συνδυασμενου με γκεμσιταμπινη και προαιρετικα με ιοντιζουσα ακτινοβολια στη θεραπεια του καρκινου
BR112020015915A8 (pt) Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
CY1111565T1 (el) Θεραπεια συνδυασμου του zd6474 με 5-fu και/ή cpt-11
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
NO20075849L (no) Fremgangsmater og preparater til behandling eller forebygging av kreft
EA201391286A1 (ru) Лечение солидных опухолей
BR112022010319A2 (pt) Uso de bi853520 no tratamento de câncer
BR112022023199A2 (pt) Certas composições químicas e métodos de uso das mesmas
MX2024008115A (es) Tratamiento conjunto para tratamiento contra el cancer.
ZA202304965B (en) Combination therapy for treating cancer
BR112021021826A8 (pt) Uso de apremilaste e um inibidor da tirosina quinase 2 no tratamento de uma doença ou um transtorno responsivo à inibição da fosfodiesterase tipo 4
JOP20200242A1 (ar) مركبات البلاديينوليد واستخداماتها
BR112022026247A2 (pt) Método para aumentar a eficácia terapêutica de um agente de imunoterapia, método de tratamento de câncer e método de inibição do crescimento de uma célula de câncer
MX2020007066A (es) Reduccion de la expresion de beta-catenina e ido para potenciar la inmunoterapia.